InMode Ltd vs Progressive Corp — how do they compare? InMode Ltd trades at $14.07 (market cap $806.05M), while Progressive Corp trades at $218.9 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 157.5× InMode Ltd's market cap, and Progressive Corp pays a 0.18% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Progressive Corp for 81 Days on average.
| INMD | PGR | |
|---|---|---|
Market Cap | $806.05M | $126.95B |
Volume | 511,446 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $16.62 | $242.16 |
52-Week Low | $12.76 | $190.40 |
Typical Hold Time | 29 Days | 81 Days |
Enterprise Value | $309.39M | $135.16B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook. The stock shows strong fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Valuation metrics appear reasonable with P/E of 10.74 and ROE of 34.94%. Recent earnings beat expectations in Q2 2026, and analyst consensus targets $222.23.
PGR presents a compelling investment case with consistent revenue growth and strong profitability. However, investors face risks from intensifying auto insurance competition and potential margin pressure. The stock's current price near resistance levels suggests limited near-term upside despite positive analyst sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →